secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kinnate Biopharma Inc. (—)
CIK:        0001797768
Form:       8-K
Filed at:   2023-07-28T23:59:59+00:00
Accession:  0001140361-23-036770
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kinnate Biopharma amends bylaws on advance notice, universal proxy, and DGCL updates
--------------------------------------------------------------------------------

- Board approved amended and restated bylaws effective July 25, 2023.
- Updates include changes to advance notice procedures for director nominations and stockholder proposals.
- Provisions revised to address SEC universal proxy rules and recent DGCL amendments.
- Exclusive forum provisions clarified; other ministerial and conforming changes made.
- No operational or financial impact; full text of bylaws filed as Exhibit 3.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1797768/000114036123036770/0001140361-23-036770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1797768/000114036123036770/brhc20056586_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-036770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer